Isatuximab Carfilzomib Lenalidomide Dexamethasone
Phase 3Small molecule
Isatuximab Carfilzomib Lenalidomide Dexamethasone is one of 39 small molecule programs targeting Multiple Myeloma. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
258 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Belamaf
GSKPhase 3
Empliciti
Bristol-Myers SquibbPhase 3
Venclexta
AbbViePhase 3
Keytruda
Merck & Co.Phase 3
Xpovio
KKaryopharm Therapeutics Inc
Phase 3
Azatiq
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Elranatamab
PfizerPhase 3
Cytosar
TevaPhase 3
BLENREP
GGlaxo Dba Glaxosmithkline
Phase 3
Sylvant
RRECORDATI GROUP
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- EEuropean Myeloma Network B.V.